Dr. Jodele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
MLC 11027
Cincinnati, OH 45229Phone+1 513-636-5917
Summary
- I am a Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's Hospital Medical Center (CCHMC). The overall focus of my research is to reduce organ toxicity in children and young adults undergoing a hematopoietic stem cell transplant (HCT). My primary research interest is transplant-associated thrombotic microangiopathy (TMA). TMA is systemic vascular endothelial injury that occurs during HCT. TMA can result in multi-organ injury and effects overall outcomes. My research effort is targeted towards understanding the pathogenesis of organ injury after HCT, developing screening and early diagnostic tools and investigating novel therapeutic interventions. I have national and international collaborations with colleagues in Nephrology, Cardiology, Critical Care, Genetics, Pharmacology, Bioinformatics. Our collaborative research on TMA has resulted in significant changes to the clinical care of transplant patients, publications, presentations at national and international scientific meetings, working committees and NIH funded research projects.
Education & Training
- Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2001 - 2004
- SUNY Downstate Health Sciences UniversityResidency, Pediatrics, 1998 - 2001
- Vilnius University Faculty of MedicineClass of 1994
Certifications & Licensure
- OH State Medical License 2004 - 2026
- CA State Medical License 2001 - 2025
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Start of enrollment: 2018 Aug 03
- Ultra-high Dose Vitamin D for HSCT Start of enrollment: 2018 Dec 10
Publications & Presentations
PubMed
- Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism.Bethany Verkamp, Sonata Jodele, Anthony Sabulski, Rebecca Marsh, Pearce Kieser
Blood. 2024-12-19 - Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT.Pietro Merli, Sonata Jodele, Eleanor Cook, Kasiani C Myers, Adam Lane
Bone Marrow Transplantation. 2024-12-03 - Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery.Kevin Todd, Spencer J Hogue, James S Tweddell, James A Reagor, Eric Mullins
Journal of Thrombosis and Haemostasis. 2024-11-12
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: